Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
China
· Delayed Price · Currency is CNY 5.88
-0.02 (-0.34%)
Apr 30, 2025, 3:04 PM CST
SHE:300039 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,473 | 1,591 | 1,117 | 1,099 | 907.1 | Upgrade
|
| Other Revenue | - | 3.03 | 2.25 | 1.29 | 0.91 | Upgrade
|
| Revenue | 1,473 | 1,594 | 1,119 | 1,101 | 908.01 | Upgrade
|
| Revenue Growth (YoY) | -7.57% | 42.47% | 1.66% | 21.21% | -36.01% | Upgrade
|
| Cost of Revenue | 272.76 | 311.82 | 247.85 | 234.1 | 180.55 | Upgrade
|
| Gross Profit | 1,201 | 1,282 | 871 | 866.48 | 727.46 | Upgrade
|
| Selling, General & Admin | 727.1 | 858.13 | 612.86 | 652.66 | 583.45 | Upgrade
|
| Research & Development | 99.79 | 95.87 | 52.97 | 79.32 | 59.12 | Upgrade
|
| Other Operating Expenses | 4.73 | 23.92 | 16.92 | 11.5 | 8.2 | Upgrade
|
| Operating Expenses | 831.62 | 972.48 | 689.51 | 747.13 | 647.45 | Upgrade
|
| Operating Income | 368.94 | 309.75 | 181.49 | 119.35 | 80.01 | Upgrade
|
| Interest Expense | - | - | - | -0.15 | -0.52 | Upgrade
|
| Interest & Investment Income | 13.98 | 60.87 | 42.66 | 44.77 | 50.93 | Upgrade
|
| Other Non Operating Income (Expenses) | 50.62 | -0.24 | -0.16 | -0.03 | -1.19 | Upgrade
|
| EBT Excluding Unusual Items | 433.54 | 370.38 | 224 | 163.94 | 129.23 | Upgrade
|
| Impairment of Goodwill | - | -9.04 | -4.75 | -4.71 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.1 | -4.54 | -6.59 | 1.8 | -12.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.26 | -0.21 | -0.17 | -0.22 | -0.07 | Upgrade
|
| Asset Writedown | -0.2 | -0.1 | - | - | - | Upgrade
|
| Other Unusual Items | - | 27.04 | 13.71 | 8.84 | 14.58 | Upgrade
|
| Pretax Income | 434.18 | 383.53 | 226.19 | 169.65 | 131.6 | Upgrade
|
| Income Tax Expense | 59.27 | 56.63 | 36.11 | 29.54 | 25.48 | Upgrade
|
| Earnings From Continuing Operations | 374.91 | 326.9 | 190.08 | 140.11 | 106.12 | Upgrade
|
| Minority Interest in Earnings | 0.67 | 0.97 | 0.72 | 0 | - | Upgrade
|
| Net Income | 375.58 | 327.87 | 190.8 | 140.11 | 106.12 | Upgrade
|
| Net Income to Common | 375.58 | 327.87 | 190.8 | 140.11 | 106.12 | Upgrade
|
| Net Income Growth | 14.55% | 71.84% | 36.18% | 32.03% | -57.72% | Upgrade
|
| Shares Outstanding (Basic) | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | Upgrade
|
| Shares Outstanding (Diluted) | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | Upgrade
|
| Shares Change (YoY) | 0.00% | -0.02% | 0.01% | 0.04% | -1.31% | Upgrade
|
| EPS (Basic) | 0.36 | 0.31 | 0.18 | 0.13 | 0.10 | Upgrade
|
| EPS (Diluted) | 0.36 | 0.31 | 0.18 | 0.13 | 0.10 | Upgrade
|
| EPS Growth | 14.54% | 71.88% | 36.17% | 31.97% | -57.16% | Upgrade
|
| Free Cash Flow | 138.43 | 353.59 | 344.8 | 83.53 | 236.71 | Upgrade
|
| Free Cash Flow Per Share | 0.13 | 0.34 | 0.33 | 0.08 | 0.23 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.060 | 0.050 | 0.030 | Upgrade
|
| Dividend Growth | - | 66.67% | 20.00% | 66.67% | -70.00% | Upgrade
|
| Gross Margin | 81.49% | 80.44% | 77.85% | 78.73% | 80.12% | Upgrade
|
| Operating Margin | 25.04% | 19.43% | 16.22% | 10.84% | 8.81% | Upgrade
|
| Profit Margin | 25.49% | 20.57% | 17.05% | 12.73% | 11.69% | Upgrade
|
| Free Cash Flow Margin | 9.40% | 22.18% | 30.82% | 7.59% | 26.07% | Upgrade
|
| EBITDA | 404.99 | 344.72 | 213.2 | 153.21 | 120.82 | Upgrade
|
| EBITDA Margin | 27.49% | 21.63% | 19.05% | 13.92% | 13.31% | Upgrade
|
| D&A For EBITDA | 36.05 | 34.97 | 31.71 | 33.86 | 40.81 | Upgrade
|
| EBIT | 368.94 | 309.75 | 181.49 | 119.35 | 80.01 | Upgrade
|
| EBIT Margin | 25.04% | 19.43% | 16.22% | 10.84% | 8.81% | Upgrade
|
| Effective Tax Rate | 13.65% | 14.77% | 15.96% | 17.41% | 19.36% | Upgrade
|
| Revenue as Reported | - | 1,594 | 1,119 | 1,101 | 908.01 | Upgrade
|
| Advertising Expenses | - | - | - | 11.24 | 7.07 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.